Heparin-induced thrombocytopenia: Overview and treatment

P and T

Volumn 33, Issue 11, 2008, Pages 642-651

  Zinkovsky, Daniel A ^d   Antonopoulos, Marilena S ^a,b,c  

^a LONG ISLAND UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; ANTIVITAMIN K; ARGATROBAN; CARDIOVASCULAR AGENT; CEPHALOSPORIN; CHLORPROPAMIDE; DANAPAROID; DIAZEPAM; DIGOXIN; FONDAPARINUX; HEPARIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; METHYLDOPA; PARACETAMOL; PENICILLIN G; PHENYTOIN; QUINIDINE; SEDATIVE AGENT; SULFONAMIDE; THIAZIDE DIURETIC AGENT; TOLBUTAMIDE; TRIMETHOPRIM; UNINDEXED DRUG; VALPROIC ACID;

ANTIBODY RESPONSE; BLEEDING; CIRCULATION; CLINICAL FEATURE; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG HALF LIFE; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPARIN INDUCED THROMBOCYTOPENIA; HEPARINIZATION; HOSPITALIZATION; HUMAN; IMMUNITY; LABORATORY TEST; MONOCYTE; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SCORING SYSTEM; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS;

EID: 57649239085     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Warkentin TE. Drug-induced immune-mediated thrombocytopenia: From purpura to thrombosis. N Engl J Med 2007;356(9):891-893.
2. Bick RL. Heparin and low molecular weight heparins. In: Bick RL, ed. Disorders of Thrombosis and Hemostasis, 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2006:359-378.
3. Levy JH, Hursting MJ. Heparin-induced thrombocytopenia, a prothrombotic disease. Hematol Oncol Clin North Am 2007;21(1):65-88.
4. Newman PM, Chong BH. Heparin-induced thrombocytopenia: New evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood 2000;96(1):182-187.
5. Jang IK, Hursting MJ. When heparins promote thrombosis: Review of heparin-induced thrombocytopenia. Circulation 2005;111(20):2671-2683.
6. Arepally GM, Mayer IM. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Blood 2001;98:1252-1254.
7. Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med 1987;316:581-589.
8. Rice L. Heparin-induced thrombocytopenia: Myths and misconceptions (that will cause trouble for you and your patient). Arch Intern Med 2004;164:1961-1964.
9. Warkentin TE. Heparin-induced thrombocytopenia. Curr Hematol Rep 2002;1:63-72.
10. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001;344:1286-1292.
11. Warkentin TE. New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest 2005;127(2 Suppl):35S-45S.
12. Warkentin TE. Heparin-induced thrombocytopenia. Hematol Oncol Clin North Am 2007;21(4):589-607.
13. Warkentin TE, Greinacher A, Koster A, et al. Treatment and pre-vention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8th ed. Chest 2008;133(6 Suppl):340S-380S.
14. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001;135(7):502-506.
15. Warkentin TE, Bernstein RA. Delayed-onset heparin-induced thrombocytopenia and cerebral thrombosis after a single administration of unfractionated heparin. N Engl J Med 2003;348(11):1067-1069.
16. Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006;4:759-765.
17. Warkentin TE. Heparin-induced thrombocytopenia: Diagnosis and management. Circulation 2004;110(18):e454-e458.
18. Warkentin TE. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Arch Pathol Lab Med 2002;126(11):1415-1423.
19. Brieger DB, Mak KH, Kottke-Marchant K, et al. Heparin-induced thrombocytopenia. J Am Coll Cardiol 1998;31(7):1449-1459.
20. Hoffbrand AV, Moss PAH, Pettit JE, eds. Essential Hematology, 5th ed. Malden, MA: Blackwell; 2006:278-289.
21. Shinton NK, ed. Desk Reference for Hematology, 2nd ed. Boca Raton, FL: CRC Press; 2008:218.
22. Hanin RI. Disorders of the platelet and vessel wall. In: Kasper DL, Braunwald E, Fauchi AS, et al., eds. Harrison's Principles of Internal Medicine, 16th ed. New York: McGraw-Hill; 2005:674.
23. Selleng K, Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med 2007;35(4):1165-1176.
24. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996;101:502-507.
25. Deitcher SRI. Antiplatelet, anticoagulant, and fibrinolytic therapy. In: Kasper DL, Braunwald E, Fauchi AS, et al., eds. Harrison's Principles of Internal Medicine, 16th ed. New York: McGraw-Hill; 2005:687-693.
26. Refludan (lepirudin injection), package insert. Wayne, NJ: Bayer HealthCare Pharmaceuticals, Inc., December 2006.
27. Greinacher A, Volpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study. Circulation 1999;99(1):73-80.
28. Lubenow N, Eichler P, Lietz T, et al. Lepirudin in patients with heparin-induced thrombocytopenia: Results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 2005;3(11):2428-2436.
29. Argatroban (Novastan), package insert. Research Triangle Park, NC: GlaxoSmithKline; July 2005.
30. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86(2):385-391.
31. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103(14):1838-1843.
32. Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003;163(15):1849-1856.
33. Angiomax (bivalirudin), package insert. Bedford, OH: BenVenue Laboratories; December 2005.
34. Kiser TH, Fish DN. Evaluation of bivalirudin treatment for heparin induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction. Pharmacotherapy 2006;26(4):452-460.
35. Warkentin TE. Danaparoid (Orgaran) for the treatment of heparin-induced thrombocytopenia (HIT) and thrombosis: Effects of in vivo thrombin and cross-linked fibrin generations, and evaluation of the clinical significance of in vitro cross-reactivity (XR) of danaparoid for HIT-IgG. Blood 1996;88(Suppl I):626a.
36. Arixtra (fondaparinux), package insert. Research Triangle Park, NC: GlaxoSmithKline; April 2008.
37. Papadopoulos S, Flynn JD, Lewis DA. Fondaparinux as a treatment option for heparin-induced thrombocytopenia. Pharmacotherapy 2007;27(6):921-926.
38. Srinivasan AF, Rice L, Bartholomew JR, et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med 2004;12;164(1):66-70.
39. Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. N Engl J Med 2006;355(8):809-817.